For Whom?
For representatives of health care payers, HTA agencies, academic research teams and market access
teams of the pharmaceutical industry or consultant companies who are involved or interested in-, or
influenced by evidence-based policy decisions in countries with economic constraints.
Why?
Evidence-based decision-making is especially important in less affluent countries with more limited health
care resources and generally poorer overall health status, as the opportunity cost of suboptimal
pharmaceutical policy decisions is higher in these countries
Brief description
The course – in parallel with providing basic insights into the theory of economic evaluation, modeling,
managed entry agreements and multi criteria decision analysis (MCDA) – will primarily be based on case
studies. Participants will develop an economic model and use it for designing managed entry agreement
scenarios and understanding their influence on the cost-effectiveness and the budget impact of
pharmaceuticals at their market entry. As the traditional economic value frameworks may be too narrow
to capture patient-centric and societal value elements, participants will develop an extended value
framework and evaluate policy scenarios by MCDA.
Participation will be face-to-face (seating is limited and is subject to the number of international
applicants) and live virtual (available only for participants outside Semmelweis University)
Lecturers: Prof. Zoltán Kaló, Assoc. Prof. András Inotai
For more information, please download our detailed brochures from here:
Applied_Health Economics_Flyer_Q1_2023_
- download our application form:Applied_Health_Economics_course_registration_2023
- fill out the form,
- send the completed form in a .pdf format to hta@semmelweis.hu via email.
Important: After sending your registration form by email, please wait for receiving your invoice first. Only after you received your invoice transfer the registration fee.
Thank you!